T20	Exp 164 197	the endothelial cell (EC) surface
T21	Exp 471 498	the nuclear receptor family
T22	Exp 659 675	their regulation
T23	Exp 590 607	The present study
T24	Exp 774 778	that
T25	Exp 863 899	the PPARalpha activators fenofibrate
T26	Exp 1132 1150	its mRNA half-life
T27	Exp 1039 1064	Both PPARalpha activators
T28	Exp 1266 1270	that
T29	Exp 1545 1572	its transcriptional control
T30	Exp 1709 1714	which
T31	Exp 1647 1663	the clinical use
T32	Exp 1600 1613	Such findings
R5	Coref Anaphora:T22 Antecedent:T4
R6	Coref Anaphora:T26 Antecedent:T13
R7	Coref Anaphora:T29 Antecedent:T17
R8	Coref Anaphora:T30 Antecedent:T33
T1	Protein 46 79	vascular cell adhesion molecule-1
T2	Protein 397 445	Peroxisome proliferator-activated receptor-alpha
T3	Protein 447 456	PPARalpha
T4	Protein 621 630	PPARalpha
T5	Protein 679 712	vascular cell adhesion molecule-1
T6	Protein 714 720	VCAM-1
T7	Protein 812 821	PPARalpha
T8	Protein 867 876	PPARalpha
T9	Protein 921 930	TNF-alpha
T10	Protein 939 945	VCAM-1
T11	Protein 1017 1026	PPARgamma
T12	Protein 1044 1053	PPARalpha
T13	Protein 1092 1098	VCAM-1
T14	Protein 1189 1195	VCAM-1
T15	Protein 1292 1298	VCAM-1
T16	Protein 1355 1364	PPARalpha
T17	Protein 1475 1484	PPARalpha
T18	Protein 1576 1582	VCAM-1
T19	Protein 1728 1737	PPARalpha
T33	Exp 1695 1707	fibric acids
